Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
© 2014 John Wiley & Sons Ltd..
The impact of lenalidomide treatment on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear. This study used time-dependent multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia (AML) progression in 215 patients with International Prognostic Scoring System (IPSS) low or intermediate-1 risk and del(5q). There were significant differences in several relevant characteristics at presentation between patients receiving (n = 86) or not receiving lenalidomide (n = 129). The 5-year time-dependent probabilities of OS and progression to AML were 62% and 31% for patients receiving lenalidomide and 42% and 25% for patients not receiving lenalidomide; differences were not statistically significant in multivariate analysis that included all variables independently associated with those outcomes (OS, P = 0·45; risk of AML, P = 0·31, respectively). Achievement of RBC transfusion independency (P = 0·069) or cytogenetic response (P = 0·021) after lenalidomide was associated with longer OS in multivariate analysis. These data clearly show that response to lenalidomide results in a substantial clinical benefit in lower risk MDS patients with del(5q). Lenalidomide treatment does not appear to increase AML risk in this population of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:166 |
|---|---|
| Enthalten in: |
British journal of haematology - 166(2014), 2 vom: 23. Juli, Seite 189-201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sánchez-García, Joaquín [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.09.2014 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.12876 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM237213923 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM237213923 | ||
| 003 | DE-627 | ||
| 005 | 20231224111203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.12876 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0790.xml |
| 035 | |a (DE-627)NLM237213923 | ||
| 035 | |a (NLM)24716538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sánchez-García, Joaquín |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.09.2014 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 John Wiley & Sons Ltd. | ||
| 520 | |a The impact of lenalidomide treatment on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear. This study used time-dependent multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia (AML) progression in 215 patients with International Prognostic Scoring System (IPSS) low or intermediate-1 risk and del(5q). There were significant differences in several relevant characteristics at presentation between patients receiving (n = 86) or not receiving lenalidomide (n = 129). The 5-year time-dependent probabilities of OS and progression to AML were 62% and 31% for patients receiving lenalidomide and 42% and 25% for patients not receiving lenalidomide; differences were not statistically significant in multivariate analysis that included all variables independently associated with those outcomes (OS, P = 0·45; risk of AML, P = 0·31, respectively). Achievement of RBC transfusion independency (P = 0·069) or cytogenetic response (P = 0·021) after lenalidomide was associated with longer OS in multivariate analysis. These data clearly show that response to lenalidomide results in a substantial clinical benefit in lower risk MDS patients with del(5q). Lenalidomide treatment does not appear to increase AML risk in this population of patients | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a deletion 5q | |
| 650 | 4 | |a lenalidomide | |
| 650 | 4 | |a myelodysplastic syndrome | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Del Cañizo, Consuelo |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Nomdedeu, Benet |e verfasserin |4 aut | |
| 700 | 1 | |a Luño, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a de Paz, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Xicoy, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Valcárcel, David |e verfasserin |4 aut | |
| 700 | 1 | |a Brunet, Salut |e verfasserin |4 aut | |
| 700 | 1 | |a Marco-Betes, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a García-Pintos, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Osorio, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Tormo, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Bailén, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Cerveró, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Diez-Campelo, María |e verfasserin |4 aut | |
| 700 | 1 | |a Such, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Arrizabalaga, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Azaceta, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Bargay, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Arilla, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Falantes, José |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano-López, Josefina |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Guillermo F |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Group on Myelodysplastic Syndromes (GES MD) |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-García, J |e investigator |4 oth | |
| 700 | 1 | |a Serrano-López, J |e investigator |4 oth | |
| 700 | 1 | |a Casaño, J |e investigator |4 oth | |
| 700 | 1 | |a del Cañizo, C |e investigator |4 oth | |
| 700 | 1 | |a Diez-Campelo, M |e investigator |4 oth | |
| 700 | 1 | |a González, J R |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Rivas, J M |e investigator |4 oth | |
| 700 | 1 | |a Sanz, G |e investigator |4 oth | |
| 700 | 1 | |a Such, E |e investigator |4 oth | |
| 700 | 1 | |a Cervera, J |e investigator |4 oth | |
| 700 | 1 | |a Senent, L |e investigator |4 oth | |
| 700 | 1 | |a Lorenzo, I |e investigator |4 oth | |
| 700 | 1 | |a Nomdedeu, B |e investigator |4 oth | |
| 700 | 1 | |a Calvo, X |e investigator |4 oth | |
| 700 | 1 | |a Belkaid, M |e investigator |4 oth | |
| 700 | 1 | |a Costa, D |e investigator |4 oth | |
| 700 | 1 | |a Nomdedeu, M |e investigator |4 oth | |
| 700 | 1 | |a Luño, E |e investigator |4 oth | |
| 700 | 1 | |a Bernal, T |e investigator |4 oth | |
| 700 | 1 | |a Sanzo, C |e investigator |4 oth | |
| 700 | 1 | |a de Paz, R |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Maraver, D |e investigator |4 oth | |
| 700 | 1 | |a Xicoy, B |e investigator |4 oth | |
| 700 | 1 | |a Jiménez, J |e investigator |4 oth | |
| 700 | 1 | |a Millá, F |e investigator |4 oth | |
| 700 | 1 | |a Valcarcel, D |e investigator |4 oth | |
| 700 | 1 | |a Vallespí, T |e investigator |4 oth | |
| 700 | 1 | |a Brunet, S |e investigator |4 oth | |
| 700 | 1 | |a Nomdedeu, J F |e investigator |4 oth | |
| 700 | 1 | |a Marco, V |e investigator |4 oth | |
| 700 | 1 | |a García-Pintos, M |e investigator |4 oth | |
| 700 | 1 | |a Font, P |e investigator |4 oth | |
| 700 | 1 | |a Osorio, S |e investigator |4 oth | |
| 700 | 1 | |a Tormo, M |e investigator |4 oth | |
| 700 | 1 | |a Calabuig, M |e investigator |4 oth | |
| 700 | 1 | |a Bailén, A |e investigator |4 oth | |
| 700 | 1 | |a Cerveró, C J |e investigator |4 oth | |
| 700 | 1 | |a Ramos, F |e investigator |4 oth | |
| 700 | 1 | |a Arrizabalaga, B |e investigator |4 oth | |
| 700 | 1 | |a Azaceta, G |e investigator |4 oth | |
| 700 | 1 | |a Bargay, J |e investigator |4 oth | |
| 700 | 1 | |a Arilla, M J |e investigator |4 oth | |
| 700 | 1 | |a Caballero, M |e investigator |4 oth | |
| 700 | 1 | |a Falantes, J |e investigator |4 oth | |
| 700 | 1 | |a Pedro, C |e investigator |4 oth | |
| 700 | 1 | |a Martínez-López, J |e investigator |4 oth | |
| 700 | 1 | |a Ardanaz, M T |e investigator |4 oth | |
| 700 | 1 | |a Collado, R |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, J A |e investigator |4 oth | |
| 700 | 1 | |a Andreu, R |e investigator |4 oth | |
| 700 | 1 | |a Benavente, C |e investigator |4 oth | |
| 700 | 1 | |a Insunza, A |e investigator |4 oth | |
| 700 | 1 | |a Amigo, M L |e investigator |4 oth | |
| 700 | 1 | |a Requena, M J |e investigator |4 oth | |
| 700 | 1 | |a Ríos, R |e investigator |4 oth | |
| 700 | 1 | |a Villalón, L |e investigator |4 oth | |
| 700 | 1 | |a Fernández-González, A |e investigator |4 oth | |
| 700 | 1 | |a Bonanad, S |e investigator |4 oth | |
| 700 | 1 | |a Marco, A |e investigator |4 oth | |
| 700 | 1 | |a Mora, A |e investigator |4 oth | |
| 700 | 1 | |a Coll, R |e investigator |4 oth | |
| 700 | 1 | |a Simiele, A |e investigator |4 oth | |
| 700 | 1 | |a González, B |e investigator |4 oth | |
| 700 | 1 | |a Gómez, V |e investigator |4 oth | |
| 700 | 1 | |a Calasanz, M J |e investigator |4 oth | |
| 700 | 1 | |a Duarte, R |e investigator |4 oth | |
| 700 | 1 | |a Bautista, G |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 166(2014), 2 vom: 23. Juli, Seite 189-201 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:166 |g year:2014 |g number:2 |g day:23 |g month:07 |g pages:189-201 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.12876 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 166 |j 2014 |e 2 |b 23 |c 07 |h 189-201 | ||